These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 12709016)
1. Apoptotic cell death in conjunction with CD80 costimulation confers uveal melanoma cells with the ability to induce immune responses. Carlring J; Shaif-Muthana M; Sisley K; Rennie IG; Murray AK Immunology; 2003 May; 109(1):41-8. PubMed ID: 12709016 [TBL] [Abstract][Full Text] [Related]
2. Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells. Shaif-Muthana M; McIntyre C; Sisley K; Rennie I; Murray A Cancer Res; 2000 Nov; 60(22):6441-7. PubMed ID: 11103811 [TBL] [Abstract][Full Text] [Related]
3. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366 [TBL] [Abstract][Full Text] [Related]
4. Identification of an Immunogenic Subset of Metastatic Uveal Melanoma. Rothermel LD; Sabesan AC; Stephens DJ; Chandran SS; Paria BC; Srivastava AK; Somerville R; Wunderlich JR; Lee CC; Xi L; Pham TH; Raffeld M; Jailwala P; Kasoji M; Kammula US Clin Cancer Res; 2016 May; 22(9):2237-49. PubMed ID: 26712692 [TBL] [Abstract][Full Text] [Related]
5. Induction and large-scale expansion of CD8+ tumor specific cytotoxic T lymphocytes from peripheral blood lymphocytes by in vitro stimulation with CD80-transfected autologous melanoma cells. Mackensen A; Wittnebel S; Veelken H; Noppen C; Spagnoli GC; Lindermann A Eur Cytokine Netw; 1999 Sep; 10(3):329-36. PubMed ID: 10477389 [TBL] [Abstract][Full Text] [Related]
6. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791 [TBL] [Abstract][Full Text] [Related]
7. Human uveal melanoma cells inhibit the immunostimulatory function of dendritic cells. Ma J; Usui Y; Takeuchi M; Okunuki Y; Kezuka T; Zhang L; Mizota A; Goto H Exp Eye Res; 2010 Oct; 91(4):491-9. PubMed ID: 20624388 [TBL] [Abstract][Full Text] [Related]
8. Effect of B7.1-transfected human colon cancer cells on the induction of autologous tumour-specific cytotoxic T cells. Miyazono Y; Kamogawa Y; Ryo K; Furukawa T; Mitsuhashi M; Yamauchi K; Kameoka T; Hayashi N J Gastroenterol Hepatol; 1999 Oct; 14(10):997-1003. PubMed ID: 10530496 [TBL] [Abstract][Full Text] [Related]
9. Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells. Bosch JJ; Iheagwara UK; Reid S; Srivastava MK; Wolf J; Lotem M; Ksander BR; Ostrand-Rosenberg S Cancer Immunol Immunother; 2010 Jan; 59(1):103-12. PubMed ID: 19557412 [TBL] [Abstract][Full Text] [Related]
10. PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. Yang W; Chen PW; Li H; Alizadeh H; Niederkorn JY Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2518-25. PubMed ID: 18296654 [TBL] [Abstract][Full Text] [Related]
11. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186 [TBL] [Abstract][Full Text] [Related]
12. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro. Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500 [TBL] [Abstract][Full Text] [Related]
13. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines. Fenton RG; Turcovski-Corrales SM; Taub DD J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360 [TBL] [Abstract][Full Text] [Related]
14. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. Li Y; McGowan P; Hellström I; Hellström KE; Chen L J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929 [TBL] [Abstract][Full Text] [Related]
15. CD80-mediated induction of immunostimulation in two ocular melanoma cell lines is augmented by interferon-gamma. Mulcahy KA; Alexander S; Platts KE; Wardle C; Sisley K; Rennie IG; Murray AK Melanoma Res; 2002 Apr; 12(2):129-38. PubMed ID: 11930109 [TBL] [Abstract][Full Text] [Related]
16. Efficient generation of autologous peripheral blood-derived cytotoxic T lymphocytes against poorly immunogenic human tumors using recombinant CD80-adenovirus together with interleukin 12 and interleukin 2. Mogi S; Ebata T; Setoguchi Y; Fujime M; Heike Y; Kohsaka T; Yagita H; Okumura K; Azuma M Clin Cancer Res; 1998 Mar; 4(3):713-20. PubMed ID: 9533541 [TBL] [Abstract][Full Text] [Related]
18. Comparison of cytokines and CD80 for enhancement of immunogenicity of cervical cancer cells. Kaufmann AM; Gissmann L; Simms P; Schreckenberger C; Qiao L Immunobiology; 2000 Nov; 202(4):339-52. PubMed ID: 11131151 [TBL] [Abstract][Full Text] [Related]
19. Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity. Smythe JA; Fink PD; Logan GJ; Lees J; Rowe PB; Alexander IE J Immunol; 1999 Sep; 163(6):3239-49. PubMed ID: 10477593 [TBL] [Abstract][Full Text] [Related]
20. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses. Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]